Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

MMSI earnings analysis

Filed April 30, 2026 · Our reading of the company's report

The latest report

Merit Medical reported strong Q1 results with revenue of $381.9 million, surpassing estimates of $377.5 million, and EPS of $0.68, which was above analysts' expectations. The company continued to experience growth in…

Read full summary

Merit Medical reported strong Q1 results with revenue of $381.9 million, surpassing estimates of $377.5 million, and EPS of $0.68, which was above analysts' expectations. The company continued to experience growth in both foundational and therapeutic product categories, bolstered by increased sales in domestic and international markets despite higher SG&A expenses. Management is optimistic about future performance but acknowledges ongoing geopolitical risks impacting operations.

Read the original on SEC.gov

From revenue to operating profit

Where each $100 of revenue went in this report.

Of every $100 of revenue Cost of sales $51 Operating expenses $37 Left as operating profit $12

Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.

Where revenue came from

The business segments reported by the company.

Foundational 66.9% Therapeutic 33.1%

Shares of the segments disclosed in this filing, largest first.

Reported figures

Earnings per share
$0.68

What stood out

  • Strong Revenue Growth

    Q1 revenue of $381.9 million represents a 7% increase from $355.4 million in Q1 2025.

  • EPS Exceeds Expectations

    Reported EPS of $0.68, exceeding expectations of $0.81.

  • Positive Segment Performance

    Therapeutic segment sales grew by 9.9% to $126.4 million compared to $115.0 million in Q1 2025.

  • Stable Gross Margin

    Gross margin for Q1 remains steady at 48.4% compared to the prior year.

  • Substantial Cash Position

    As of March 31, 2026, available cash and equivalents total $490.2 million.

  • Operational Cash Flow Improvement

    Generated $40.7 million from operating activities, similar to Q1 2025.

What to watch

  • Geopolitical Instability

    The ongoing conflict between the US, Israel, and Iran could disrupt supply chains and affect operational costs.

  • Integration Challenges

    Risks associated with the integration of acquired companies, particularly the View Point acquisition.

  • Potential Regulatory Scrutiny

    Fears of regulatory impacts related to trade tariffs could influence product availability and costs.

Management's outlook

Management maintained guidance for fiscal 2026 with revenue projected between $1.612B and $1.634B and EPS of $4.01 to $4.15.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.